Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients

Peritoneal Dialysis International

Volumn 25, Issue 6, 2005, Pages 564-569

  Theodoridis, Marios ^a,b   Passadakis, Ploumis ^a   Kriki, Pelagia ^a   Panagoutsos, Stelios ^a   Yannatos, Evangelos ^a   Kantartzi, Konstantia ^a   Sivridis, Dimitris ^a   Vargemezis, Vasilis ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Anemia; Chronic renal failure; Darbepoetin alfa; Novel erythropoiesis stimulating protein (NESP); Recombinant human erythropoietin

Indexed keywords

C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATOCRIT; HUMAN; KIDNEY FAILURE; MAINTENANCE DRUG DOSE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 30944457315     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500612     Document Type: Article

References (27)

1. Caro J, Brown S, Miller O, Murray T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93:449-58.
2. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrobano F. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanis Society of Nephrology. J Am Soc Nephrol 2000; 11:335-42.
3. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-16.
4. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10:610-19.
5. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5):1-50.
6. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1(8635):425-7.
7. Boelaert JR, Schurgers ML, Matthys EG, Belpaire FM, Daneels RF, De Cre MJ, et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1989; 9:95-8.
8. Bommer J, Barth H-P, Zeier M, Mandelbaum A, Bommer G, Ritz E, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88:136-43.
9. Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG, Kleinman JG, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339:578-83.
10. Egrie JC, Grant JR, Gillies DK, Aoki KH, Strickland TW. The role of carbohydrate on the biological activity of erythropoietin [Abstract]. Glycoconj J 1993; 10:263.
11. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10:2392-5.
12. Macdougall IC. Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20:375-81.
13. Vanrenterghem Y, Bárány P, Mann JF, Kerr PG, Wilson J, Baker NF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dosing frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62:2167-75.
14. Canaud B. Darbepoetin alfa dose requirements for i.v. and s.c. administration are equivalent in anaemic dialysis patients [Abstract M319]. Nephrol Dial Transplant 2002; 17(Suppl 12):137.
15. Vanrenterghem Y, Jadoul M, Foret M, Walker R, and the European/Australian NESP 2000-0144 Study Group. Novel erythropoiesis stimulating protein (NESP) administered once every 3 weeks by the intravenous or subcutaneous route maintains hemoglobin (Hb) in dialysis patients [Abstract]. J Am Soc Nephrol 2003; 12:A1878.
16. Braun J, on behalf of the 20000144 Study Group. Darbepoetin alfa administered once every 4 weeks maintains Hb levels in patients with chronic kidney disease (CKD) receiving dialysis [Abstract M317]. Nephrol Dial Transplant 2002; 17(Suppl 12):136.
17. Aljama P, Bommer J, Canaud B, Carrera F, Eckardt K-U, Hörl WH, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001; 16(Suppl 3):22-8.
18. Pereira BJG. Optimization of pre-ESRD care: the key to improved dialysis outcomes. Kidney Int 2000; 57:351-65.
19. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, et al. Randomized, controlled trial of darbepoetin alfa in the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40:110-18.
20. Graf H, Lacombe J-L, Braun J, Gomes da Costa AA. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients [Abstract]. J Am Soc Nephrol 2000; 11:1317A.
21. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60:741-7.
22. Brunkhorst R, Bommer J, Braun J, Haag-Weber M, Gill C, Wagner J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004; 19:1224-30.
23. Eckardt KU. Pathophysiology of renal anemia. Clin Nephrol 2000; 53(1 Suppl):S2-8.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for peritoneal dialysis adequacy, 2000. Am J Kidney Dis 2001; 37(Suppl 1):S65-136.
25. Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003; 18: 576-81.
26. Locatelli F, Canaud B, Giacardy F, Martin-Malo A, Baker N, Wilson J. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18:362-9.
27. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004; 19:898-903.